We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

0 hedge funds and large institutions have $223K invested in TransCode Therapeutics in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

90% less capital invested

Capital invested by funds: $2.27M → $223K (-$2.05M)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$1.42M
2
WVP
Worth Venture Partners
New Jersey
-$357K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$220K
4
RAM
Redmond Asset Management
Virginia
-$100K
5
KJHP
K.J. Harrison & Partners
Ontario, Canada
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$51K – – –
CWM
2
Cahill Wealth Management
Michigan
$22.9K – – –
HF
3
HRT Financial
New York
$17K – – –
SSWM
4
Sheets Smith Wealth Management
North Carolina
$16.8K – – –
State Street
5
State Street
Massachusetts
$14.1K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$14K – – –
Two Sigma Investments
7
Two Sigma Investments
New York
$13.1K – – –
Goldman Sachs
8
Goldman Sachs
New York
$11.5K – – –
VF
9
Virtu Financial
New York
$11K – – –
BlackRock
10
BlackRock
New York
$10.6K – – –
SC
11
Shay Capital
New York
$10.1K – – –
Millennium Management
12
Millennium Management
New York
$9K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$9K – – –
TCM
14
Triumph Capital Management
Colorado
$6.73K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$4K – – –
Morgan Stanley
16
Morgan Stanley
New York
$784 – – –
UBS Group
17
UBS Group
Switzerland
$777 – – –
Wells Fargo
18
Wells Fargo
California
$34 – – –
ACM
19
AIGH Capital Management
Maryland
– -$1.42M -2 Closed
KJHP
20
K.J. Harrison & Partners
Ontario, Canada
– -$22K – –
RAM
21
Redmond Asset Management
Virginia
– -$100K – –
Vanguard Group
22
Vanguard Group
Pennsylvania
– -$220K – –
WVP
23
Worth Venture Partners
New Jersey
– -$357K – –

RNAZ Hedge Fund Activity: Q4 2022 in Review

0 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2022, worth a combined $223K — down 90% from $2.27M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of RNAZ and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.42M sold.

  • 0 institutional investors held TransCode Therapeutics (RNAZ) as of Q4 2022, down from 1 in Q3 2022.
  • Funds reported $223K of TransCode Therapeutics stock for Q4 2022, down 90% quarter-over-quarter.
  • 0 funds opened new TransCode Therapeutics positions in Q4 2022 and 1 closed out, a net change of -1 holder.
  • The largest TransCode Therapeutics seller in Q4 2022 was AIGH Capital Management, an estimated $1.42M sold.

Based on aggregated 13F filings for Q4 2022.